QS Research · Michael Burry's Scion Capital analyst template · 2006
Medline Inc. (MDLN)
As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data
Report price $39.17 (close 2026-11-16); latest close $37.04 (2026-11-20), -5.4% since the report; figures re-marked at the latest close
Conclusion: AVOID
Conviction medium · base case -31% · downside -48% · upside +16%
The market is still paying 44.5x FY2025 net income and 21.8x TTM EBITDA for a distributor earning 6.4% ROIC on 25.7% gross margins, so the good news is already in the price. That is why the call is AVOID. The base case is $25.44 (-35.1%), P/E at 28.9x, the peer median P/E. The downside case is $19.08 (-51.3%), the base case's multiple on -25.0% earnings. The upside case is $43.09 (+10.0%), +10% earnings at today's P/E of 44.5x — the best case adds a tenth while the base and downside sit well below the $39.17 close. The call also runs against large tracked-fund positions: SurgoCap Partners LP has 7.5% of its book in the name, trimmed at the quarter end, though 13F holdings are as of the quarter end and filed up to 45 days later. With a quality score of 20/100, 6.4% ROIC and free cash flow margin of 6.2%, a 28.9x peer multiple — not 44.5x — is the fair anchor.
Key numbers
- Share price: $37.04
- Market cap: $48.72B
- Latest financial period: TTM to Sep 26, 2026
- Revenue (TTM): $30.68B
- EV / EBITDA (TTM): 20.8x
- P/E (FY Dec 2025): 42.1x
- FCF yield: 3.9%
- Price / book: 4.13x
- Earnings-quality flags (FY Dec 2025): none flagged
- EV / FCF (TTM): 30.4x
- Revenue growth (latest fiscal year): +11.5%
- ROIC (TTM): 6.4%
The 15 boxes
- ✓ 1. Long-form business notes
Medline is a 1966-founded med-surg manufacturer-distributor with two segments, Medline Brand and Supply Chain Solutions, spanning about 335,000 products and tied together by multi-year Prime Vendor contracts. It monetizes product breadth, Medline Brand margin conversion, and supply-chain services, supported by a 70-site distribution network, owned trucks, and a large U.S. commercial team. From FY2023 to FY2025 revenue rose from $23.23B to $28.43B and operating income from $1.25B to $2.21B. TTM to Sep 26 2026 revenue was $30.68B, but TTM operating income was $1.74B, below FY2025.
- ✓ 2. Competitive advantage
Medline's claimed advantage is structural rather than brand-led: it is both a manufacturer (about one-third of Medline Brand products in 30 plants, 24 in North America) and a distributor with 70 facilities and over 2,100 MedTrans trucks, and it argues rivals reliant on third-party distribution lack that vertical scale. The margin record does not yet prove pricing power: gross margin went ~25.3% (FY2023) to ~26.4% (FY2025) and back to ~25.7% (TTM to 2026-09-26), while operating margin fell to ~5.7% TTM from ~7.8% FY2025 even as revenue rose $2.25B. Advantage looks real in sourcing breadth and distribution density, but bargaining power sits largely with GPOs and large customers, and competition is explicitly on price against McKesson, Cardinal Health, Owens & Minor and Henry Schein.
- ✓ 3. 10-Q takeaways
Q3 2026 net sales rose 10.4% to $7,856M with organic sales up 10.5%, but GAAP net income fell 1.2% to $318M as gross margin compressed to 24.5% and SG&A rose; Adjusted EBITDA rose 11.8% to $960M. Nine-month net income fell 28.8% to $696M, including $316M of net Tracy fire losses, while net IEEPA tariff refund benefits were $324M. Management raised FY2026 organic sales growth guidance to 10.0%-10.5% and reaffirmed Adjusted EBITDA of $3.3B-$3.4B, and the board authorized a $1B buyback in October 2026. The 10-Q states no material changes to risk factors.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.